Healios K.K. announced that Healios and medical group have entered into a letter of intent for a basic agreement for joint research to utilize the technology and culture supernatant owned by Healios. The purpose of this LOI is to confirm the understanding between the with respect to a joint research agreement under which Healios will provide regenerative medicine technology and raw materials to AND medical for use in the development of a new therapy. Healios will receive JPY 180 million yen as joint research expenses.

The two parties will continue negotiations toward the conclusion of this agreement based on this LOI.